<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02333721</url>
  </required_header>
  <id_info>
    <org_study_id>2015-03</org_study_id>
    <nct_id>NCT02333721</nct_id>
  </id_info>
  <brief_title>Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Middle or Upper Third Gastric Cancer</brief_title>
  <acronym>LSPLN</acronym>
  <official_title>Study on Long-term Outcome of Laparoscopic Spleen-Preserving D2 Lymphadenectomy With and Without No. 10 Lymph Node Dissection for Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the short-term, long-term and oncological outcomes of
      laparoscopic spleen-preserving No. 10 lymph node dissection in a left-sided approach for
      advanced middle or upper third gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized comparison of laparoscopic spleen-preserving No. 10 lymph node
      dissection for gastric cancer will be performed, to evaluate the short-term, long-term and
      oncological outcomes. The evaluation parameters are perioperative clinical efficacy,
      postoperative life quality, immune function and 3-year survival and recurrence rates.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity and mortality</measure>
    <time_frame>30 days; 36 months</time_frame>
    <description>The early postoperative complication and mortality are defined as the event observed within 30 days after surgery, while the time frame for late complication is the period from postoperative day 31th to the end of month 36th.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival rate</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year recurrence pattern</measure>
    <time_frame>36 months</time_frame>
    <description>Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first ambulation</measure>
    <time_frame>10 days</time_frame>
    <description>The data of postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of splenectomy</measure>
    <time_frame>1 day</time_frame>
    <description>splenectomy performing by severe injury to the splenic vessels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of injury to splenic vessels</measure>
    <time_frame>1 day</time_frame>
    <description>intraoperative injury to the splenic vessels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of lymph node dissection</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of weight</measure>
    <time_frame>12 months</time_frame>
    <description>The variation of weight on postoperative 3, 6, 9 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The daily highest body temperature</measure>
    <time_frame>7 days</time_frame>
    <description>The daily highest body temperature before discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first flatus</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first liquid diet</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to soft diet</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of abdominal drainage</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of positive lymph nodes</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative lymph node dissection time</measure>
    <time_frame>1 day</time_frame>
    <description>intraoperative No.10 lymph node dissection time includes infrapyloric area lymph node,suprapancreatic area lymph node,splenic hilar area lymph node, cardial area lymph node)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative injury</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of use of titanium clip</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of conversion to laparotomy</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of cholesterol</measure>
    <time_frame>12 months</time_frame>
    <description>The variation of cholesterol on postoperative 3, 6, 9 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of albumin</measure>
    <time_frame>12 months</time_frame>
    <description>The variation of albumin on postoperative 3, 6, 9 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The results of endoscopy</measure>
    <time_frame>12 months</time_frame>
    <description>the results of endoscopy on postoperative 3 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The values of white blood cell count</measure>
    <time_frame>7 days</time_frame>
    <description>the values of white blood cell count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The values of hemoglobin</measure>
    <time_frame>7 days</time_frame>
    <description>and the values of hemoglobin from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The values of C-reactive protein</measure>
    <time_frame>7 days</time_frame>
    <description>and the values of C-reactive protein from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The values of prealbumin</measure>
    <time_frame>7 days</time_frame>
    <description>and the values of prealbumin from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The values of relevant immune cytokines</measure>
    <time_frame>7 days</time_frame>
    <description>and the values of relevant immune cytokines including T cell percentage, T-helper lymphocytes (CD4+) percentage, T-suppressor lymphocytes (CD8+) percentage, natural killer (NK) cells percentage from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">536</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>D2 Lymphadenectomy including No. 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D2 lymphadenectomy excluding No. 10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D2 lymphadenectomy including No. 10</intervention_name>
    <description>After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy</description>
    <arm_group_label>D2 Lymphadenectomy including No. 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D2 lymphadenectomy excluding No. 10</intervention_name>
    <description>After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy</description>
    <arm_group_label>D2 lymphadenectomy excluding No. 10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 to 75 years

          -  Primary distal gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell,
             or poorly differentiated) confirmed pathologically by endoscopic biopsy

          -  cT2-4a, N0-3, M0 at preoperative evaluation according to the American Joint Committee
             on Cancer (AJCC) Cancer Staging Manual Seventh Edition

          -  No distant metastasis is observed. And the spleen, pancreas or other adjacent organs
             are not involved by the tumor.

          -  Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)

          -  American Society of Anesthesiology score (ASA) class I, II, or III

          -  Written informed consent

        Exclusion Criteria:

          -  Women during pregnancy or breast-feeding

          -  Severe mental disorder

          -  History of previous upper abdominal surgery (except laparoscopic cholecystectomy)

          -  History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal
             dissection

          -  Enlarged or bulky regional lymph node diameter over 3cm by preoperative imaging

          -  History of other malignant disease within past five years

          -  History of previous neoadjuvant chemotherapy or radiotherapy

          -  History of unstable angina or myocardial infarction within past six months

          -  History of cerebrovascular accident within past six months

          -  History of continuous systematic administration of corticosteroids within one month

          -  Requirement of simultaneous surgery for other disease

          -  Emergency surgery due to complication (bleeding, obstruction or perforation) caused by
             gastric cancer

          -  FEV1ï¼œ50% of predicted values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changming Huang, M.D.,Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Fujian Medical University Union Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 25, 2014</study_first_submitted>
  <study_first_submitted_qc>January 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University Union Hospital</investigator_affiliation>
    <investigator_full_name>Chang-Ming Huang</investigator_full_name>
    <investigator_title>Director, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Laparoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

